Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 462,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II/III, Phase II, and Phase III trial results, and an expected patent expiration.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 2%, and the average probability a drug advances from Phase III is 13.8%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.5 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 103 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for pancreatic cancer, followed by Roche
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Surgery
10 Ablation or embolization
11 Radiation therapy
11 Chemotherapy
11 Targeted therapy
12 Immunotherapy
12 Drugs used specifically for the treatment of PNETs
13 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
34 RECENT EVENTS AND ANALYST OPINION
34 Motixafortide for Pancreatic Cancer (January 24, 2020)
35 Lynparza for Pancreatic Cancer (December 17, 2019)
36 Pegilodecakin for Pancreatic Cancer (October 16, 2019)
37 Acelarin for Pancreatic Cancer (August 20, 2019)
38 Mavorixafor for Pancreatic Cancer (July 17, 2019)
39 Napabucasin for Pancreatic Cancer (July 1, 2019)
40 Abraxane for Pancreatic Cancer (June 2, 2019)
41 Lynparza for Pancreatic Cancer (June 2, 2019)
42 NanoKnife System for Pancreatic Cancer (May 13, 2019)
43 MVT-5873 for Pancreatic Cancer (May 8, 2019)
45 KEY UPCOMING EVENTS
46 KEY REGULATORY EVENTS
46 Lynparza Gets US OK For Pancreatic Cancer
47 PROBABILITY OF SUCCESS
48 LICENSING AND ASSET ACQUISITION DEALS
48 Cytocom Goes Public Via Merger With Cleveland BioLabs
48 Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
48 TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
49 Processa Licenses IP For Next-Generation Irinotecan From Aposense
49 Bristol Myers Squibb declines to exercise Agios Pharmaceuticals opt-in right for AG-270
49 DeMelle Licenses Pancreatic Cancer Candidate From Moffit
49 Taiho Acquires Asian Rights To Arcus IO Candidate
50 Tyme, Eagle Collaborate On Development Of Pancreatic Cancer Drug
50 Astellas Taps Pandion In Pancreas Immunomodulator Deal
51 REVENUE OPPORTUNITY
53 CLINICAL TRIAL LANDSCAPE
54 Sponsors by status
55 Sponsors by phase
56 Recent events
57 BIBLIOGRAPHY
57 Prescription information
59 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
19 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
19 Figure 3: Pipeline drugs for pancreatic cancer, by company
20 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
20 Figure 5: Pipeline drugs for pancreatic cancer, by classification
35 Figure 6: Motixafortide for Pancreatic Cancer (January 24, 2020): Phase Ib/II – w/Atezolizumab
37 Figure 7: Pegilodecakin for Pancreatic Cancer (October 16, 2019): Phase III – SEQUOIA (w/FOLFOX)
42 Figure 8: Lynparza for Pancreatic Cancer (June 2, 2019): Phase III – POLO
45 Figure 9: Key upcoming events in pancreatic cancer
47 Figure 10: Probability of success in the pancreatic cancer pipeline
53 Figure 11: Clinical trials in pancreatic cancer
53 Figure 12: Top 10 drugs for clinical trials in pancreatic cancer
54 Figure 13: Top 10 companies for clinical trials in pancreatic cancer
54 Figure 14: Trial locations in pancreatic cancer
55 Figure 15: Pancreatic cancer trials status
56 Figure 16: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of pancreatic cancer, 2019–28
17 Table 2: Marketed drugs for pancreatic cancer
21 Table 3: Pipeline drugs for pancreatic cancer in the US
34 Table 4: Motixafortide for Pancreatic Cancer (January 24, 2020)
35 Table 5: Lynparza for Pancreatic Cancer (December 17, 2019)
36 Table 6: Pegilodecakin for Pancreatic Cancer (October 16, 2019)
37 Table 7: Acelarin for Pancreatic Cancer (August 20, 2019)
38 Table 8: Mavorixafor for Pancreatic Cancer (July 17, 2019)
39 Table 9: Napabucasin for Pancreatic Cancer (July 1, 2019)
40 Table 10: Abraxane for Pancreatic Cancer (June 2, 2019)
41 Table 11: Lynparza for Pancreatic Cancer (June 2, 2019)
43 Table 12: NanoKnife System for Pancreatic Cancer (May 13, 2019)
44 Table 13: MVT-5873 for Pancreatic Cancer (May 8, 2019)
51 Table 14: Historical global sales, by drug ($m), 2015–19
52 Table 15: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Dengue Vaccines 
Sign up to the